To determine how tumor cell-derived IL-34 blocks the ICIs in colon and breast cancer, researchers used CRISPR-Cas9 technology to create IL-34-deficient CT26 and 4T1 cell lines, respectively. This evidence concerns the gene IL34 and breast carcinoma.